Efficacy and safety of once-weekly semaglutide 2 · 0 mg versus 1 · 0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial - Frías, J P; Auerbach, P; Bajaj, H S (Lancet Diabetes Endocrinol, 2021)